Since the UK Prospective Diabetes Study (UKPDS), it has been known that the progressive deterioration of insulin secretion over time leads to the failure of non-insulin therapies, necessitating insulin intensification in patients with T2DM (1) (Figure 1). The gene discussed is INS; the disease is diabetes mellitus.